Opinion|Videos|January 24, 2025
Choosing Bispecifics in 3L Treatment Setting R/R FL
Panelists discuss the use of bispecifics in the third-line setting for relapsed/refractory follicular lymphoma (R/R FL), exploring how often they are utilized and how bispecifics fit into the treatment paradigm compared with other options like chimeric antigen receptor (CAR) T, EZH2 inhibitors, and Bruton tyrosine kinase (BTK) inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Moving into in the third-line setting, we have many options now including CAR T, bispecifics, EZH2 inhibitors, BTK inhibitors; let’s first focus on the bispecifics. Dr Khan, how often are you utilizing the bispecifics in the R/R FL setting? How do the bispecifics fit into your treatment paradigm compared with these other agents?
- What factors influence your decision when selecting between mosunetuzumab and epcoritamab?
- When selecting between mosunetuzumab and epcoritamab what are key factors to consider?
Advertisement
Related to this article
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
A 3-year, $225K award will focus on improving quality of life for patients living with long-term effects of cancer treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
3
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5